A retrospective comparison of clinical outcomes and satisfaction using reconstituted recombinant gonadotropins (rFSH) or cartridge rFSH with a pen device in donor oocyte cycles

Current Medical Research and Opinion

Volumn 23, Issue 4, 2007, Pages 865-870

  Christianson, M S ^a   Barker, M A ^b   Schouweiler, C ^c   Lindheim, Steven R ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cartridge pen device; GnRH antagonists; IVF ET; Oocyte donation; rFSH

Indexed keywords

CONTRACEPTIVE AGENT; GANIRELIX; GONADORELIN ANTAGONIST; GONADOTROPIN DERIVATIVE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DEVICE; DONOR; FEMALE; FERTILIZATION IN VITRO; HUMAN; IMPLANTATION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; OOCYTE; OVARY FOLLICLE CELL; OVULATION INDUCTION; PATIENT SATISFACTION; PREGNANCY; RECIPIENT; TREATMENT OUTCOME;

ADULT; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; MENSTRUAL CYCLE; MIDDLE AGED; OOCYTE DONATION; OVULATION INDUCTION; PATIENT SATISFACTION; PREGNANCY; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34247327712     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X178784     Document Type: Article

References (35)

1. Daya S. Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol 2004;3:161-71
2. Bassett RM, Driebergen R. Continued improvements in the quality of follitropin alfa, recombinant human FSH. Reprod Biomed Online 2005;10:169-77
3. Out HJ, Mannaerts BMJL, Driessen SGAJ, et al. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in-vitro fertilization than urinary gonadotropins. Fertil Steril 1997;68:138-42
4. Bergh C, Howles CM, Borg K, et al. Recombinant human follicle stimulating hormone (R-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP]: results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum Reprod 1997;12:2133-9
5. Daya S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil Steril 2002;77:711-4
6. Dickey RP, Thornton M, Nichols J, et al. Comparison of the efficacy and safety of a highly purified human follicle-stimulating hormone (Bravelle) and recombinant follitropin-beta for in vitro fertilization: a prospective, randomized study. Fertil Steril 2002;77:1202-8
7. The North American Follistim Study Group (2003). An aqueous formulation of recombinant human FSH is more efficient than a freeze-dried cake formulation in clomiphene-resistant women with anovulation. Reprod BioMed Online [in press]
8. Al-Inany H, Aboulghar M, Mansour R, et al. Meta-analysis of recombinant versus urinary-derived FSH: an update. Hum Reprod 2003;18:305-13
9. Kadiri A, Chraibi A, Marouan F, et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM subjects with secondary failure to oral hypoglycemic agents. Diabetes Res Clin Pract 1998;41:15-23
10. Bohannon NJ. Insulin delivery using pen devices - simple to use tools may help young and old alike. Postgrad Med 1999;106:57-68
11. Pang S, Kaplan B, Karande V, et al.; The Follistim Pen COH Study Group. Administration of recombinant human FSH (solution in cartridge) with a pen device in women undergoing ovarian stimulation. Reprod BioMed Online 2003;7:319-26
12. Somkuti SG, Schertz JC, Moore M, et al. Patient experience with follitropin alfa prefilled pen versus previously used injectable gonadotropins for ovulation induction in oligoovulatory women. Curr Med Res Opin 2006;22:1981-91
13. Platteau P, Laurent E, Albano C, et al. An open, randomized, single-centre study to compare the efficacy and convenience of follitropin beta administered by a pen device with follitropin alfa administered by a conventional syringe in women undergoing ovarian stimulation for JVF/ICSI. Hum Reprod 2003;102:978-84
14. Kettel LM, Scholl G, Bonaventura L, et al. Administration of recombinant human FSH (solution in cartridge) with a pen device in women undergoing ovarian stimulation. Reprod BioMed Online 2004;9:373-80
15. Voortman G, van de Post J, Scoemaker RC, et al. Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (PuregonR) by pen-injector and syringe. Hum Reprod 1999;17;1698-702
16. Schover LR , Collins RL, Quigley MM, et al. Psychological follow-up of women evaluated as oocyte donors. Hum Reprod 1991;6:1487-91
17. Soderstrom-Anttila V. Follow-up study of Finnish volunteer oocyte donors concerning their attitudes to oocyte donation. Hum Reprod 1995;10:3073-6
18. Rosenberg H, Epstein Y. Follow-up study of anonymous ovum donors. Hum Reprod 1995;10:2741-7
19. Fielding D, Handley S, Duqueno L, et al. Motivation, attitudes, and experience of donation: a follow-up of women donating eggs in assisted conception treatment. J Community Appl Soc Psychol 1998;8;273-87
20. Kalfoglou AL, Gittelsohn J. A qualitative follow-up study of women's experiences with oocyte donation. Hum Reprod 2000;15:798-805
21. Patrick M, Smith A, Moyer WR, et al. Anonymous oocyte donation: a follow-up questionnaire. Fertil Steril 2001;75:1034-6
22. Klock SC, Stout JE, Davidson M. Psychological characteristics and factors related to willingness to donate again among anonymous oocyte donors. Fertil Steril 2003;79:1312-6
23. Lindheim S, Frumovitz M, Sauer MV. Recruitment and screening policies and procedures used to establish a paid donor oocyte registry. Hum Reprod 1998;13:2020-4
24. Sauer MV. Oocyte donation; reviewing a decade of growth and development. Semin Reprod Endocrinol 1995;13:79-84
25. Fauser B, Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist co-treatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 2005;83:1607-11
26. Borm G, Mannaerts B; The European Orgalutran Study Group. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe, and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000;15:1490-8
27. Fluker M, Grifo J, Leader A, et al.; The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75:38-45
28. Lindheim SR, Morales AJ. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod 2003;18:2048-51
29. Ricciarelli E, Sanchez M, Martinez M, et al. Impact of the gonadotropin-releasing hormone antagonist in oocyte donation cycles. Fertil Steril 2003;73:18-22
30. Al Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002;17:874-5
31. Acevedo B, Sanchez M, Gomez JL, et al. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertil Steril 2004;82:343-7
32. Cedrin-Durnerin 1, Grange-Dujardin D, Laffy A, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2004;19:1979-84
33. Prapas N, Prapas Y, Panagiotidis Y, et al. GnRH agonist versus GnRH antagonist I oocyte donation cycles: a prospective randomized study. Hum Reprod 2005;20:1516-20
34. Propst AM, Bates W, Robinson RD, et al. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer. Fertil Steril 2006;86:58-63
35. Blake D, Proctor M, Johnson N, et al. Cleavage stage versus blastocyst stage embryo transfer in assisted conception. Cochrane Database Syst Rev; CD002118, 2005